Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DSP-5336 + Fluconazole |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DSP-5336 | DSP 5336|DSP5336 | MEN1-KMT2A Inhibitor 8 | DSP-5336 binds to Menin (MEN1) and inhibits its interaction with MLL (KMT2A), potentially leading to decreased growth of tumor cells harboring MLL (KMT2A) rearrangements or NPM1 mutations (Blood (2021) 138 (Supplement 1): 3339). | |
| Fluconazole | Biocanol | Not Available |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04988555 | Phase Ib/II | DSP-5336 DSP-5336 + Fluconazole Azacitidine + DSP-5336 + Venetoclax DSP-5336 + Gilteritinib Azacitidine + DSP-5336 + Fluconazole + Venetoclax | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Recruiting | USA | ITA | GBR | FRA | ESP | CHE | CAN | BEL | 4 |